Filing Flows › 20/20 Biolabs (AIDX) › Q2 2026 › vs Q2 2025
20/20 Biolabs (AIDX) Q2 2026 vs Q2 2025 (year over year)
20/20 Biolabs's revenue rose $196K (+37%) from $535K in Q2 2025 to $731K in Q2 2026. The biggest changes: OneTest +$223K (+47%); BioCheck −$6K (-15%).
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| OneTest | $696K | $473K | $223K | +47% |
| BioCheck | $35K | $41K | −$6K | -15% |
| Revenue | $731K | $535K | $196K | +37% |
| Net loss | $1.5M | $841K | $665K | +79% |
| Costs & expenses | $2.2M | $1.4M | $856K | +62% |
| Operating costs | $2.0M | $1.4M | $594K | +43% |
| Interest & other, net | $262K | −$5K | $267K | — |
| Cost of revenue | $426K | $372K | $54K | +15% |
| Research & development | $258K | $194K | $64K | +33% |
| SG&A | $1.3M | $815K | $477K | +58% |
| Operating cash sources | $1.5M | $841K | $665K | +79% |
| Depreciation & amortization | $12K | $15K | −$3K | -21% |
| Share-based compensation | $371K | $130K | $242K | +186% |
| Working capital & other | $517K | $162K | $356K | +220% |
| Cash used in operations | $605K | $534K | $71K | +13% |
| Net loss absorbed | $1.5M | $841K | $665K | +79% |
Questions
How much did 20/20 Biolabs's revenue grow year over year in Q2 2026?
20/20 Biolabs's revenue rose $196K (+37%) from $535K in Q2 2025 to $731K in Q2 2026.
What drove 20/20 Biolabs's revenue change in Q2 2026?
OneTest +$223K (+47%); BioCheck −$6K (-15%).